Your shopping cart is currently empty

m-PEG-NHS ester (MW 350) is utilized to modify active molecules, enhancing their antigenicity and immunogenicity, thus aiding in the preparation of injectable formulations. Modification of serine protease lumbrokinase (LK) with m-PEG-NHS ester does not affect its fibrinolytic and thrombolytic activities, indicating promising potential for application.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry | |
| 100 mg | Inquiry | Inquiry | Inquiry |
| Description | m-PEG-NHS ester (MW 350) is utilized to modify active molecules, enhancing their antigenicity and immunogenicity, thus aiding in the preparation of injectable formulations. Modification of serine protease lumbrokinase (LK) with m-PEG-NHS ester does not affect its fibrinolytic and thrombolytic activities, indicating promising potential for application. |
| Synonyms | mPEG-Succinimidyl ester (MW 350), mPEG-SC (MW 350), m-PEG-NHS ester (MW 350) |
| Molecular Weight | 350(Average) |
| Formula | (C2H4O)nC7H9NO5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.